Top Markets
#1 Purr Purr +56.44%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +49.99%
#4 Non-Playable Coin Non-Playable Coin +31.31%
#5 Kinetiq Kinetiq +26.80%
#6 StonkBroker StonkBroker +26.42%
#7 ApeX ApeX +24.48%
#8 Morpho Morpho +22.27%
#9 TENDIES TENDIES +21.98%
#10 OriginTrail OriginTrail +21.44%
Coin of the day
Purr Purr
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Kedudukan dalam Saham #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Harga Saham
$2.65
Disegerakkan terakhir: 2024-04-03
Modal Pasaran
$115.71M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Kinnate Biopharma Inc. (KNTE)

Kategori

Healthcare
Hasil untuk Kinnate Biopharma Inc. (KNTE)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Kinnate Biopharma Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Kinnate Biopharma Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH